#psychedelicresearch — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #psychedelicresearch, aggregated by home.social.
-
DATE: May 12, 2026 at 10:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Are the benefits of psychedelics exaggerated? A new study highlights the problem of selection bias
A study comparing psychedelic enthusiasts and people from the general population (who also had psychedelic experiences) found that the enthusiasts tended to report much greater positive quality-of-life effects. The enthusiasts also showed higher openness, extraversion, and agreeableness. This indicates that recruitment strategies in psychedelic research that lean towards including enthusiasts may shape the outcomes obtained in those studies. The paper was published in the Journal of Psychoactive Drugs.
Psychedelic drugs are substances that can strongly alter perception, mood, thinking, and the sense of self. They may change how people experience colors, sounds, time, memories, emotions, and the meaning of events. Classic psychedelics include LSD, psilocybin from “magic mushrooms,” DMT, and mescaline. These substances mainly act on serotonin receptors in the brain.
In research settings, psychedelics are being studied for possible therapeutic use in conditions such as depression, PTSD, anxiety, and substance use disorders. Their effects depend heavily on dose, personality, expectations, mental state, physical setting, and social support. Psychedelics can also carry risks, including panic, confusion, dangerous behavior during intoxication, worsening of some psychiatric conditions, and legal consequences where they are prohibited.
Study author Jonathan Bendz and his colleagues noted that many studies of psychedelic users report extraordinarily positive self-reported effects. However, they suggest that this might represent an exaggeration of the real effects caused by biased selection, or even self-selection, of study participants. The issue is that the effects of psychedelics can only be tested on individuals who agree to use them. These participants tend to be individuals who have already had especially positive experiences with psychedelic use.
To examine this hypothesis, these researchers conducted a study comparing whether the self-reported quality-of-life impact of psychedelic experiences differed between a convenience sample of psychedelic enthusiasts and a group of people from the general population recruited via Prolific. They also wanted to see whether the difference between the two groups remained after controlling for mindset, setting, motivation to use psychedelic drugs, and personality traits.
The enthusiast group consisted of 583 individuals recruited through an anonymous survey posted on the Facebook and Instagram pages of a Swedish nonprofit organization that disseminates information about psychedelic science (Nätverket för Psykedelisk Vetenskap). A snowball sampling approach was used to reach more participants. The general population group consisted of 599 individuals recruited via Prolific (an online survey platform). They were required to have prior psychedelic experience, but were not recruited from a specific psychedelic community.
Study participants completed assessments of the quality-of-life impact of their psychedelic experiences (e.g., “How has your most meaningful psychedelic experience affected the quality of your relationship with… family, friends, yourself, society, and nature?”). They also answered questions regarding their mindset and physical setting during the experience (“To what extent did you experience your mindset/environment to be optimal?”), their motivation (“What was your motivation for using a psychedelic substance?”), and their personality (using the IPIP-NEO-30 assessment).
Results showed that the psychedelic enthusiasts tended to report a much higher quality-of-life impact from their psychedelic experiences compared to the Prolific group. The enthusiast group also reported having a more optimal mindset and setting during their trips, and they were more likely to report taking the drugs for personal growth rather than for fun. Finally, the enthusiasts tended to be more open to new experiences, extraverted, and agreeable than the participants from the Prolific group.
Even after using a statistical model to account for these differences in personality, mindset, setting, and motivation, simply belonging to the enthusiast group remained the strongest predictor of reporting a high quality-of-life impact.
“As expected, participants recruited from an enthusiast-leaning channel reported considerably greater benefits [of psychedelic use] than those recruited from a general-population platform. Even after controlling for mindset, setting, motivation, and personality, sample membership remained the strongest predictor of quality-of-life impact,” the study authors concluded.
“The persistent effect of sample membership suggests that the two groups differ in additional ways not captured by our measures, for example in cultural expectations, social context, or demographic composition, shaping reported outcomes. These results underscore the need for caution when interpreting findings from psychedelic studies that rely on highly engaged user populations.”
The study sheds light on important methodological issues that studies of psychedelic effects face. However, the authors note some limitations. For example, the two groups had demographic differences; the general sample was overwhelmingly from the United States, while the enthusiast sample lacked country-of-residence data for most participants (though a portion resided in Sweden). This introduces the possibility of cross-cultural differences influencing the results.
Additionally, it should be noted that the Prolific sample likely included many psychedelic enthusiasts as well. Because of this, the difference between the two groups in this study likely underestimates the true difference between the general population and psychedelic enthusiasts.
The paper, “Selection Bias in Psychedelic Research: Comparing Self-Reported Quality-Of-Life Impact Between Enthusiasts and a General Population Sample,” was authored by Jonathan Bendz, Linus Schäfer, David Sjöström, Sverker Sikström, and Petri Kajonius.
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Psychedelics #SelectionBias #QualityOfLife #PsychedelicResearch #StudyBias #OpenMindedness #PersonalityTraits #MentalHealthResearch #TherapeuticPsychedelics #ScientificCaution
-
DATE: May 12, 2026 at 10:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Are the benefits of psychedelics exaggerated? A new study highlights the problem of selection bias
A study comparing psychedelic enthusiasts and people from the general population (who also had psychedelic experiences) found that the enthusiasts tended to report much greater positive quality-of-life effects. The enthusiasts also showed higher openness, extraversion, and agreeableness. This indicates that recruitment strategies in psychedelic research that lean towards including enthusiasts may shape the outcomes obtained in those studies. The paper was published in the Journal of Psychoactive Drugs.
Psychedelic drugs are substances that can strongly alter perception, mood, thinking, and the sense of self. They may change how people experience colors, sounds, time, memories, emotions, and the meaning of events. Classic psychedelics include LSD, psilocybin from “magic mushrooms,” DMT, and mescaline. These substances mainly act on serotonin receptors in the brain.
In research settings, psychedelics are being studied for possible therapeutic use in conditions such as depression, PTSD, anxiety, and substance use disorders. Their effects depend heavily on dose, personality, expectations, mental state, physical setting, and social support. Psychedelics can also carry risks, including panic, confusion, dangerous behavior during intoxication, worsening of some psychiatric conditions, and legal consequences where they are prohibited.
Study author Jonathan Bendz and his colleagues noted that many studies of psychedelic users report extraordinarily positive self-reported effects. However, they suggest that this might represent an exaggeration of the real effects caused by biased selection, or even self-selection, of study participants. The issue is that the effects of psychedelics can only be tested on individuals who agree to use them. These participants tend to be individuals who have already had especially positive experiences with psychedelic use.
To examine this hypothesis, these researchers conducted a study comparing whether the self-reported quality-of-life impact of psychedelic experiences differed between a convenience sample of psychedelic enthusiasts and a group of people from the general population recruited via Prolific. They also wanted to see whether the difference between the two groups remained after controlling for mindset, setting, motivation to use psychedelic drugs, and personality traits.
The enthusiast group consisted of 583 individuals recruited through an anonymous survey posted on the Facebook and Instagram pages of a Swedish nonprofit organization that disseminates information about psychedelic science (Nätverket för Psykedelisk Vetenskap). A snowball sampling approach was used to reach more participants. The general population group consisted of 599 individuals recruited via Prolific (an online survey platform). They were required to have prior psychedelic experience, but were not recruited from a specific psychedelic community.
Study participants completed assessments of the quality-of-life impact of their psychedelic experiences (e.g., “How has your most meaningful psychedelic experience affected the quality of your relationship with… family, friends, yourself, society, and nature?”). They also answered questions regarding their mindset and physical setting during the experience (“To what extent did you experience your mindset/environment to be optimal?”), their motivation (“What was your motivation for using a psychedelic substance?”), and their personality (using the IPIP-NEO-30 assessment).
Results showed that the psychedelic enthusiasts tended to report a much higher quality-of-life impact from their psychedelic experiences compared to the Prolific group. The enthusiast group also reported having a more optimal mindset and setting during their trips, and they were more likely to report taking the drugs for personal growth rather than for fun. Finally, the enthusiasts tended to be more open to new experiences, extraverted, and agreeable than the participants from the Prolific group.
Even after using a statistical model to account for these differences in personality, mindset, setting, and motivation, simply belonging to the enthusiast group remained the strongest predictor of reporting a high quality-of-life impact.
“As expected, participants recruited from an enthusiast-leaning channel reported considerably greater benefits [of psychedelic use] than those recruited from a general-population platform. Even after controlling for mindset, setting, motivation, and personality, sample membership remained the strongest predictor of quality-of-life impact,” the study authors concluded.
“The persistent effect of sample membership suggests that the two groups differ in additional ways not captured by our measures, for example in cultural expectations, social context, or demographic composition, shaping reported outcomes. These results underscore the need for caution when interpreting findings from psychedelic studies that rely on highly engaged user populations.”
The study sheds light on important methodological issues that studies of psychedelic effects face. However, the authors note some limitations. For example, the two groups had demographic differences; the general sample was overwhelmingly from the United States, while the enthusiast sample lacked country-of-residence data for most participants (though a portion resided in Sweden). This introduces the possibility of cross-cultural differences influencing the results.
Additionally, it should be noted that the Prolific sample likely included many psychedelic enthusiasts as well. Because of this, the difference between the two groups in this study likely underestimates the true difference between the general population and psychedelic enthusiasts.
The paper, “Selection Bias in Psychedelic Research: Comparing Self-Reported Quality-Of-Life Impact Between Enthusiasts and a General Population Sample,” was authored by Jonathan Bendz, Linus Schäfer, David Sjöström, Sverker Sikström, and Petri Kajonius.
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Psychedelics #SelectionBias #QualityOfLife #PsychedelicResearch #StudyBias #OpenMindedness #PersonalityTraits #MentalHealthResearch #TherapeuticPsychedelics #ScientificCaution
-
DATE: May 12, 2026 at 10:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Are the benefits of psychedelics exaggerated? A new study highlights the problem of selection bias
A study comparing psychedelic enthusiasts and people from the general population (who also had psychedelic experiences) found that the enthusiasts tended to report much greater positive quality-of-life effects. The enthusiasts also showed higher openness, extraversion, and agreeableness. This indicates that recruitment strategies in psychedelic research that lean towards including enthusiasts may shape the outcomes obtained in those studies. The paper was published in the Journal of Psychoactive Drugs.
Psychedelic drugs are substances that can strongly alter perception, mood, thinking, and the sense of self. They may change how people experience colors, sounds, time, memories, emotions, and the meaning of events. Classic psychedelics include LSD, psilocybin from “magic mushrooms,” DMT, and mescaline. These substances mainly act on serotonin receptors in the brain.
In research settings, psychedelics are being studied for possible therapeutic use in conditions such as depression, PTSD, anxiety, and substance use disorders. Their effects depend heavily on dose, personality, expectations, mental state, physical setting, and social support. Psychedelics can also carry risks, including panic, confusion, dangerous behavior during intoxication, worsening of some psychiatric conditions, and legal consequences where they are prohibited.
Study author Jonathan Bendz and his colleagues noted that many studies of psychedelic users report extraordinarily positive self-reported effects. However, they suggest that this might represent an exaggeration of the real effects caused by biased selection, or even self-selection, of study participants. The issue is that the effects of psychedelics can only be tested on individuals who agree to use them. These participants tend to be individuals who have already had especially positive experiences with psychedelic use.
To examine this hypothesis, these researchers conducted a study comparing whether the self-reported quality-of-life impact of psychedelic experiences differed between a convenience sample of psychedelic enthusiasts and a group of people from the general population recruited via Prolific. They also wanted to see whether the difference between the two groups remained after controlling for mindset, setting, motivation to use psychedelic drugs, and personality traits.
The enthusiast group consisted of 583 individuals recruited through an anonymous survey posted on the Facebook and Instagram pages of a Swedish nonprofit organization that disseminates information about psychedelic science (Nätverket för Psykedelisk Vetenskap). A snowball sampling approach was used to reach more participants. The general population group consisted of 599 individuals recruited via Prolific (an online survey platform). They were required to have prior psychedelic experience, but were not recruited from a specific psychedelic community.
Study participants completed assessments of the quality-of-life impact of their psychedelic experiences (e.g., “How has your most meaningful psychedelic experience affected the quality of your relationship with… family, friends, yourself, society, and nature?”). They also answered questions regarding their mindset and physical setting during the experience (“To what extent did you experience your mindset/environment to be optimal?”), their motivation (“What was your motivation for using a psychedelic substance?”), and their personality (using the IPIP-NEO-30 assessment).
Results showed that the psychedelic enthusiasts tended to report a much higher quality-of-life impact from their psychedelic experiences compared to the Prolific group. The enthusiast group also reported having a more optimal mindset and setting during their trips, and they were more likely to report taking the drugs for personal growth rather than for fun. Finally, the enthusiasts tended to be more open to new experiences, extraverted, and agreeable than the participants from the Prolific group.
Even after using a statistical model to account for these differences in personality, mindset, setting, and motivation, simply belonging to the enthusiast group remained the strongest predictor of reporting a high quality-of-life impact.
“As expected, participants recruited from an enthusiast-leaning channel reported considerably greater benefits [of psychedelic use] than those recruited from a general-population platform. Even after controlling for mindset, setting, motivation, and personality, sample membership remained the strongest predictor of quality-of-life impact,” the study authors concluded.
“The persistent effect of sample membership suggests that the two groups differ in additional ways not captured by our measures, for example in cultural expectations, social context, or demographic composition, shaping reported outcomes. These results underscore the need for caution when interpreting findings from psychedelic studies that rely on highly engaged user populations.”
The study sheds light on important methodological issues that studies of psychedelic effects face. However, the authors note some limitations. For example, the two groups had demographic differences; the general sample was overwhelmingly from the United States, while the enthusiast sample lacked country-of-residence data for most participants (though a portion resided in Sweden). This introduces the possibility of cross-cultural differences influencing the results.
Additionally, it should be noted that the Prolific sample likely included many psychedelic enthusiasts as well. Because of this, the difference between the two groups in this study likely underestimates the true difference between the general population and psychedelic enthusiasts.
The paper, “Selection Bias in Psychedelic Research: Comparing Self-Reported Quality-Of-Life Impact Between Enthusiasts and a General Population Sample,” was authored by Jonathan Bendz, Linus Schäfer, David Sjöström, Sverker Sikström, and Petri Kajonius.
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: http://subscribe-article-digests.clinicians-exchange.org
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
It's primitive... but it works... mostly...
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Psychedelics #SelectionBias #QualityOfLife #PsychedelicResearch #StudyBias #OpenMindedness #PersonalityTraits #MentalHealthResearch #TherapeuticPsychedelics #ScientificCaution
-
Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes
New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.
#PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression
https://newsletter.tf/psychedelics-low-sensory-changes-therapy-outcomes/
-
Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes
New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.
#PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression
https://newsletter.tf/psychedelics-low-sensory-changes-therapy-outcomes/
-
Scientists now believe small sensory changes from psychedelics are key to therapy, not just side effects. This is a big shift from older ideas.
#PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression
https://newsletter.tf/psychedelics-low-sensory-changes-therapy-outcomes/ -
LSD shows promise for reducing anxiety in drugmaker’s midstage study
WASHINGTON (AP) — LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for…
#NewsBeep #News #Health #anxietysymptoms #CA #Canada #foodanddrugadministration #FrederickBarrett #generalizedanxietydisorder #LSD #psychedelicdrug #Psychedelicresearch #researchers #studymethods #symptomsofanxiety
https://www.newsbeep.com/ca/119632/ -
Here's the video of my August 6th Q&A on autism and psychedelics, hosted by the lovely folks at the OPEN Foundation.
#psychedelics #psychedelictherapy #psychedelicscience #psychedelicresearch #autism #consciousness #autistic #cognition #transformation #humanpotential #autismawareness #neurodivergence #neurodiversity #neuroqueer #psychology #psychotherapy
-
OPEN Foundation hosted me and my esteemed colleague Dr. Alicia Danforth for a conversation on autism and psychedelics. Here's the video!
#psychedelics #psychedelictherapy #psychedelicresearch #autism #autistic #neurodiversity #neurodivergence #psychology #therapy #consciousness #cognition #transformation #humanpotential #neuroqueer
-
This coming Monday, May 19, the OPEN Foundation will be hosting me and my esteemed friend & colleague Dr. Alicia Danforth for a conversation about autism & psychedelics!
It's free, it's on Zoom, and everything else I know about it can be found here:
https://open-foundation.org/events/online/autism-and-psychedelics-a-conversation/#autistic #autisticwellbeing #autisticvoices #mentalhealth #psychology #psychotherapy #psychedelics #psychedelictherapy #psychedelicresearch #psychedelicscience #Consciousness #cognition #neurodiversity #neurodivergence
-
Ayahuasca, a traditional Amazonian brew known for its psychedelic effects, appears to enhance certain aspects of memory, according to a recent study. This memory boost was selective, as it did not increase false memories or their general feeling of familiarity with the scenes.
Read Full Article
#Ayahuasca #MemoryEnhancement #PsychedelicResearch #AmazonianTradition #Mindfulness https://www.psypost.org/ayahuasca-may-enhance-memory-recollection-in-experienced-users/
Reenviado desde Science News
(https://t.me/experienciainterdimensional/7760) -
https://pubmed.ncbi.nlm.nih.gov/39868914/ El camaleón de la ketamina: historia, farmacología y el valor disputado de la experiencia / The ketamine chameleon: history, pharmacology, and the contested value of experience (Diep, et al, 2025) #ketamine #ketamina #psychedelics #psicodelico #psychedelic #psychedelicresearch #terapiaketamina
-
https://pubmed.ncbi.nlm.nih.gov/39608193/ Effect of intravenous ketamine on suicidality in adults with treatment-resistant depression: A real world effectiveness study (Chen-Li, et al, 2024) #ketamine #suicidality #depression #mentalhealth #psychedelic #psychedelics #psychedelicresearch #ketaminetherapy
-
https://pubmed.ncbi.nlm.nih.gov/39549887/ Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials (Shi, et al, 2024) #ketamine #depression #mentslhealth #psychedelic #psychedelics #psychedelicresearch #neuroscience #ect #bipolar #ketaminetherapy #ketamineassistedtherapy
-
https://www.researchgate.net/publication/331555962_Beyond_LSD_A_Broader_Psychedelic_Zeitgeist_during_the_Early_to_Mid-20th_Century Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century (Aday, et al, 2019) on the first #psychedelic research in 1887. 1887!!! #psychedelics #psychedelicresearch #mescaline
-
https://www.researchgate.net/publication/331555962_Beyond_LSD_A_Broader_Psychedelic_Zeitgeist_during_the_Early_to_Mid-20th_Century Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century (Aday, et al, 2019) on the first #psychedelic research in 1887. 1887!!! #psychedelics #psychedelicresearch #mescaline
-
https://www.researchgate.net/publication/331555962_Beyond_LSD_A_Broader_Psychedelic_Zeitgeist_during_the_Early_to_Mid-20th_Century Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century (Aday, et al, 2019) on the first #psychedelic research in 1887. 1887!!! #psychedelics #psychedelicresearch #mescaline
-
https://www.researchgate.net/publication/331555962_Beyond_LSD_A_Broader_Psychedelic_Zeitgeist_during_the_Early_to_Mid-20th_Century Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century (Aday, et al, 2019) on the first #psychedelic research in 1887. 1887!!! #psychedelics #psychedelicresearch #mescaline
-
MindMed, a pharmaceutical corporation that is not MAPS/Lykos, has several FDA-approved psychedelic studies in the works — #lsd analog for #anxiety and #depression and r-mdma form of #mdma for autism spectrum disorders #psychedelics #psychedelic #psychedelicresearch #psychedelicassistedtherapy #psychedelicmentalhealth #fda #phase2 #phase3 https://ir.mindmed.co/news-events/press-releases/detail/158/mindmed-reports-second-quarter-2024-financial-results-and-business-updates
-
https://pubmed.ncbi.nlm.nih.gov/39098303/ Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence (Caliman-Fontes, et al, 2024) #ketamine #catatonia #psychedelic #psychedelics #psychedelicresearch #ketaminetherapy
-
https://pubmed.ncbi.nlm.nih.gov/39062250/ A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope? (Pardossi, et al, 2024) #ketamine #esketamine #adolescents #depression #neuroscience #psychedelic #psychedelics #litreview #ketaminetherapy #psychedelicresearch #fda #mdd
-
Psilocybin desynchronizes the human brain
https://www.nature.com/articles/s41586-024-07624-5
#Psilocybin #Neuroplasticity #BrainConnectivity #Psychedelics #Serotonin #MentalHealth #Therapeutics #fMRI #Neuroscience #FunctionalMapping #Hippocampus #ClinicalTrials #Depression #Addiction #Anxiety #Synaptogenesis #Glutamate #BrainResearch #Cortex #Subcortex #EgoDissolution #SpaceTimePerception #Neurobiology #TherapeuticMechanisms #BrainNetworks #PrecisionMapping #BrainChanges #PsychedelicResearch #BrainFunction
-
Psilocybin desynchronizes the human brain
https://www.nature.com/articles/s41586-024-07624-5
#Psilocybin #Neuroplasticity #BrainConnectivity #Psychedelics #Serotonin #MentalHealth #Therapeutics #fMRI #Neuroscience #FunctionalMapping #Hippocampus #ClinicalTrials #Depression #Addiction #Anxiety #Synaptogenesis #Glutamate #BrainResearch #Cortex #Subcortex #EgoDissolution #SpaceTimePerception #Neurobiology #TherapeuticMechanisms #BrainNetworks #PrecisionMapping #BrainChanges #PsychedelicResearch #BrainFunction
-
Psilocybin desynchronizes the human brain
https://www.nature.com/articles/s41586-024-07624-5
#Psilocybin #Neuroplasticity #BrainConnectivity #Psychedelics #Serotonin #MentalHealth #Therapeutics #fMRI #Neuroscience #FunctionalMapping #Hippocampus #ClinicalTrials #Depression #Addiction #Anxiety #Synaptogenesis #Glutamate #BrainResearch #Cortex #Subcortex #EgoDissolution #SpaceTimePerception #Neurobiology #TherapeuticMechanisms #BrainNetworks #PrecisionMapping #BrainChanges #PsychedelicResearch #BrainFunction
-
Psilocybin desynchronizes the human brain
https://www.nature.com/articles/s41586-024-07624-5
#Psilocybin #Neuroplasticity #BrainConnectivity #Psychedelics #Serotonin #MentalHealth #Therapeutics #fMRI #Neuroscience #FunctionalMapping #Hippocampus #ClinicalTrials #Depression #Addiction #Anxiety #Synaptogenesis #Glutamate #BrainResearch #Cortex #Subcortex #EgoDissolution #SpaceTimePerception #Neurobiology #TherapeuticMechanisms #BrainNetworks #PrecisionMapping #BrainChanges #PsychedelicResearch #BrainFunction
-
Psilocybin desynchronizes the human brain
https://www.nature.com/articles/s41586-024-07624-5
#Psilocybin #Neuroplasticity #BrainConnectivity #Psychedelics #Serotonin #MentalHealth #Therapeutics #fMRI #Neuroscience #FunctionalMapping #Hippocampus #ClinicalTrials #Depression #Addiction #Anxiety #Synaptogenesis #Glutamate #BrainResearch #Cortex #Subcortex #EgoDissolution #SpaceTimePerception #Neurobiology #TherapeuticMechanisms #BrainNetworks #PrecisionMapping #BrainChanges #PsychedelicResearch #BrainFunction
-
https://pubmed.ncbi.nlm.nih.gov/38984875/ Magic of the Mushrooms: Effects of Psilocybin Decriminalization (Bhave, et al, 2024) #mushrooms #psilocybin #psychedelic #psychedelics #psychedelicresearch #lsd #mdma #decrim #magicmushrooms
-
https://pubmed.ncbi.nlm.nih.gov/38981574/ Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A Systematic Review of Animal Models of Depression (De Jager, et al, 2024) #ketamine #neuroplasticity #brains #electroshock #depression #neurogenesis #bdnf #brains #neuroscience #psychedelic #psychedelics #psychedelicresearch #fda #ketaminetherapy #psychedelictherapy
-
https://pubmed.ncbi.nlm.nih.gov/38981574/ Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A Systematic Review of Animal Models of Depression (De Jager, et al, 2024) #ketamine #neuroplasticity #brains #electroshock #depression #neurogenesis #bdnf #brains #neuroscience #psychedelic #psychedelics #psychedelicresearch #fda #ketaminetherapy #psychedelictherapy
-
https://pubmed.ncbi.nlm.nih.gov/38981574/ Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A Systematic Review of Animal Models of Depression (De Jager, et al, 2024) #ketamine #neuroplasticity #brains #electroshock #depression #neurogenesis #bdnf #brains #neuroscience #psychedelic #psychedelics #psychedelicresearch #fda #ketaminetherapy #psychedelictherapy
-
https://pubmed.ncbi.nlm.nih.gov/38981574/ Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A Systematic Review of Animal Models of Depression (De Jager, et al, 2024) #ketamine #neuroplasticity #brains #electroshock #depression #neurogenesis #bdnf #brains #neuroscience #psychedelic #psychedelics #psychedelicresearch #fda #ketaminetherapy #psychedelictherapy
-
https://pubmed.ncbi.nlm.nih.gov/38981574/ Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A Systematic Review of Animal Models of Depression (De Jager, et al, 2024) #ketamine #neuroplasticity #brains #electroshock #depression #neurogenesis #bdnf #brains #neuroscience #psychedelic #psychedelics #psychedelicresearch #fda #ketaminetherapy #psychedelictherapy
-
https://www.sciencedirect.com/science/article/pii/S221315821930227X Frontopolar cortex activation associated with pessimistic future-thinking in adults with major depressive disorder (Katayama, et al, 2019) #neuroscience #brains #depression #DefaultModeNetwork #ketamine #psychedelics #psychedelic #fda #psychedelicresearch #majordepressivedisorder
-
Thalamocortical functional connectivity and rapid antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression (Tu, et al, 2024) in which some functional connectivity increases (BA9) and some decreases (BA10, related to #DefaultModeNetwork ) shown #ketamine #brains #neuroscience #psychedelics #psychedelic #psychedelicresearch #ketaminetherapy #depression https://pubmed.ncbi.nlm.nih.gov/38971895/
-
https://pubmed.ncbi.nlm.nih.gov/38807690/ Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review (Yu, et al, 2024) #psychedelics #psychedelic #mdma #ayahausca #lsd #psychedelicexperience #fda #neuroscience #mysticalexperience #brains #DefaultModeNetwork #psychedelicresearch #psilocybin
-
https://pubmed.ncbi.nlm.nih.gov/38926480/ Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis (Basedow, et al, 2024) #mdma #psychedelics #fda #psychedelicresearch #psychedelic in which acute MDMA effect found to affect memory, leaving executive functions and attention unaffected. #brains #neuroscience #MDMAtherapy #ptsd #trauma #cognitiveperformance #cognition #psychedelictherapy
-
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820305 Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression A Secondary Analysis of a Randomized Clinical Trial (Jha, et al, 2024) #ketamine #psychedelic #psychedelics #depression #ECT #fda #psychedelicresearch #ketaminetherapy #NeuroScience
-
https://pubmed.ncbi.nlm.nih.gov/38858391/
A meta-analysis of the effects of #ketamine on #suicidal ideation in #depression patients (Shen, et al, 2024) #psychedelic #psychedelics #psychedelicresearch #psychedelictherapy #ketaminetherapy #ketamineassistedpsychotherapy -
https://www.nature.com/articles/s41386-024-01895-2 Ketamine induced synaptic plasticity operates independently of long-term potentiation (Piazza, et al, 2024) #ketamine #psychedelic #psychedelic #fda #antidepressant #ketaminetherapy #ketamineassistedpsychotherapy #psychedelicresearch #psychedelictherapy #brains #synapticPlasticity #neuroscience #psychedelicassistedpsychotherapy
-
https://www.nature.com/articles/s41467-023-37463-3 Characterizing brain dynamics during ketamine-induced dissociation and subsequent interactions with propofol using human intracranial neurophysiology (Tian, et al, 2023) #ketamine #brains #psychedelic #psychedelics #brainwaves #neuroscience #braincircuits #psychedelic #psychedelics #psychedelicresearch
-
https://youtu.be/DiHeBbOs-AU #mdma #psychedelics #Psilocybin #cannabis #lsd #ketamine #mdmaassistedtherapy #fda #ketamineassistedpsychotherapy #psychedelicassistedpsychotherapy #grief #deathanxiety #existentialdread #psychedelic #psychedelics #psychedelictherapy #psychedelicresearch The fact that people have measurable changes in thoughts, feelings, emotions, behaviors and MEANING after psychedelic therapy when supported by another human is measurable, even if obvious. #dosed #palliativecare #hospice
-
https://pubmed.ncbi.nlm.nih.gov/37259521/ Retrospective review of the efficacy for sublingual #ketamine in the treatment of chronic low back pain defined by a cause and central functional pain symptom focused clinical model (Johnson, et al, 2024) #lowbackpain #painmanagment #movementdysfunction #centralfunctionalpain #movementtherapy #psychedelics #psychedelic #psychedelicresearch #ketaminetherapy #chronicpain
-
@theropologist @ItsThatDeafGuy @rothko #welp at least I fed it mostly well-sourced #Psychedelicresearch -and #psychedelic #litreview
-
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-publishes-123000561.html June 2024: American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression & suicidality #ketamine #psychopharmacology #ascp2024 #psychedelics #psychedelic #psychedelicresearch #fda — Are the studies funded by NRx comparing #cognitivebehavioraltherapy ?#psychedelictherapy
-
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-publishes-123000561.html June 2024: American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression & suicidality #ketamine #psychopharmacology #ascp2024 #psychedelics #psychedelic #psychedelicresearch #fda — Are the studies funded by NRx comparing #cognitivebehavioraltherapy ?#psychedelictherapy
-
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-publishes-123000561.html June 2024: American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression & suicidality #ketamine #psychopharmacology #ascp2024 #psychedelics #psychedelic #psychedelicresearch #fda — Are the studies funded by NRx comparing #cognitivebehavioraltherapy ?#psychedelictherapy
-
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-publishes-123000561.html June 2024: American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression & suicidality #ketamine #psychopharmacology #ascp2024 #psychedelics #psychedelic #psychedelicresearch #fda — Are the studies funded by NRx comparing #cognitivebehavioraltherapy ?#psychedelictherapy
-
https://pubmed.ncbi.nlm.nih.gov/38858386/ Planar cell polarity proteins mediate ketamine-induced restoration of glutamatergic synapses in prefrontal cortical neurons in a mouse model for chronic stress (Freitas,et al, 2024) #ketamine #chronicstress #stress #ketaminetherapy #psychedelics #psychedelic #psychedelicresearch #research #depression #majordepressivedisorder
-
https://pubmed.ncbi.nlm.nih.gov/38858391/ A meta-analysis of the effects of ketamine on suicidal ideation in depression patients (Shen, et al, 2024) #ketamine #suicidality #psychedelic #psychedelics #psychedelicresearch #ketaminetherapy #depression #metaanalysis #research Note: Presumably you’re not going to rely solely on a medicine if dealing with suicidality. Human psychotherapy and support is essential parts of ongoing mental health.